Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cyclacel Pharmaceuti (NQ: CYCCP ) 9.020 UNCHANGED Last Price Updated: 3:54 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 4 Open 9.020 Bid (Size) 8.010 (1) Ask (Size) 9.650 (2) Prev. Close 9.020 Today's Range 9.020 - 9.020 52wk Range 5.250 - 22.05 Shares Outstanding N/A Dividend Yield 6.65% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions June 26, 2024 Lengthens Patent Exclusivity of Plogosertib until August 2040 From Cyclacel Via GlobeNewswire Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting June 04, 2024 From Cyclacel Via GlobeNewswire Performance YTD -45.30% -45.30% 1 Month +20.43% +20.43% 3 Month -21.57% -21.57% 6 Month -54.56% -54.56% 1 Year -35.57% -35.57% More News Read More Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer June 03, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update May 14, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results May 08, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules May 02, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules April 30, 2024 From Cyclacel Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session April 12, 2024 Via Benzinga Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer April 01, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 19, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results March 13, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 March 07, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit March 06, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference February 20, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer January 30, 2024 From Cyclacel Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session January 11, 2024 Via Benzinga Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement January 08, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024 January 02, 2024 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules December 22, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions December 18, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Announces Reverse Stock Split December 12, 2023 From Cyclacel Via GlobeNewswire Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC November 30, 2023 From Cyclacel Via GlobeNewswire Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q November 28, 2023 From Cyclacel Via GlobeNewswire Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update November 13, 2023 From Cyclacel Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session November 09, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.